相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
V Makker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study
J. C-H. Yang et al.
ANNALS OF ONCOLOGY (2021)
Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial
Hans-Joachim Schmoll et al.
JAMA ONCOLOGY (2021)
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
Richard S. Finn et al.
CLINICAL CANCER RESEARCH (2021)
A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study)
P. Pautier et al.
EUROPEAN JOURNAL OF CANCER (2020)
B cells are associated with survival and immunotherapy response in sarcoma
Florent Petitprez et al.
NATURE (2020)
Complement Signals Determine Opposite Effects of B Cells in Chemotherapy-Induced Immunity
Yiwen Lu et al.
CELL (2020)
TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy
Joseph G. Skeate et al.
FRONTIERS IN IMMUNOLOGY (2020)
Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study
Jean-Yves Blay et al.
BRITISH JOURNAL OF CANCER (2019)
Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes
Eisuke Kobayashi et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
Tertiary lymphoid structures in the era of cancer immunotherapy
Catherine Sautes-Fridman et al.
NATURE REVIEWS CANCER (2019)
Context-dependent roles of complement in cancer
Lubka T. Roumenina et al.
NATURE REVIEWS CANCER (2019)
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dal Fukurnura et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Kabir A. Khan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
Masahiro Matsuki et al.
CANCER MEDICINE (2018)
Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma
Akira Kawai et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2017)
The immune contexture in cancer prognosis and treatment
Wolf H. Fridman et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Gene expression markers of Tumor Infiltrating Leukocytes
Patrick Danaher et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
T-Cell Infiltration and Clonality Correlate With Programmed Cell Death Protein 1 and Programmed Death-Ligand 1 Expression in Patients With Soft Tissue Sarcomas
Seth M. Pollack et al.
CANCER (2017)
In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab
Shigeto Ueda et al.
BRITISH JOURNAL OF CANCER (2016)
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
Patrick Schoffski et al.
LANCET (2016)
Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression
Etienne Becht et al.
GENOME BIOLOGY (2016)
A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors
Shinji Nakamichi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment
Sandra P. D'Angelo et al.
HUMAN PATHOLOGY (2015)
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents - Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study
Sophie Postel-Vinay et al.
EUROPEAN JOURNAL OF CANCER (2014)
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Krishnansu S. Tewari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer
J. -C. Soria et al.
ANNALS OF ONCOLOGY (2013)
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Giovanni Germano et al.
CANCER CELL (2013)
Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials
Herbert I. Hurwitz et al.
ONCOLOGIST (2013)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf et al.
LANCET (2012)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
分享论文
